Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
ModeX Therapeutics (NASDAQ: OPK) announced dosing of the first patient in a Phase 1/2a clinical trial (NCT07110584) of MDX2004, a first-in-class trispecific antibody-fusion protein designed as a T cell "rejuvenator."
MDX2004 engages CD3, CD28 and binds 4-1BB as a ligand to stimulate stem and memory T cells; the trial will evaluate safety, tolerability and biologic activity in advanced cancers. Two MDX2004 posters are scheduled at the SITC Annual Meeting, Nov 5-9, 2025.
OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and nine months ended September 30, 2025 after U.S. market close on Wednesday, October 29, 2025.
Senior management will give a business update and discuss results and financial guidance on a conference call and live audio webcast starting at 4:30 p.m. Eastern on October 29. OPKO encourages pre-registration to receive a unique PIN for immediate access; dial-in options are 833-630-0584 (U.S.) and 412-317-1815 (International). A telephone replay is available until November 5, 2025 (passcode 8678248), and a webcast replay will be posted about one hour after the live call.
Labcorp (NYSE: LH) has completed the acquisition of select oncology and clinical testing assets from BioReference Health, a subsidiary of OPKO Health (Nasdaq: OPK). The transaction is valued at up to $225 million, comprising $192.5 million paid at closing and a potential $32.5 million performance-based earnout.
The acquisition strengthens Labcorp's oncology testing portfolio and expands its diagnostic capabilities. BioReference Health will retain its core clinical testing operations in NY/NJ and its 4Kscore® Test franchise, which generated approximately $300 million in revenue for 2024. OPKO plans to use part of the proceeds to fund its expanded share repurchase program.
OPKO Health (NASDAQ: OPK) reported Q2 2025 financial results with total revenues of $156.8 million, down from $182.2 million in Q2 2024. The company posted a net loss of $148.4 million ($0.19 per share), including a $91.7 million non-recurring expense related to convertible note exchange.
Key developments include Merck's advancement of Phase 1 Epstein-Barr virus vaccine trial, ModeX's progress in immuno-oncology portfolio, and promising preclinical data for OPK-88006 in diabetes treatment. The FDA approved a supplemental application for the 4KScore® Test, and the Board authorized an additional $100 million for stock repurchase, bringing total capacity to $200 million.
The Pharmaceuticals segment generated $40.7 million in product revenue, while Diagnostics revenue was $101.1 million. Cash position stood at $285.4 million as of June 30, 2025.
OPKO Health (NASDAQ:OPK) has scheduled its Second Quarter 2025 financial results announcement for July 31, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss operating and financial results for the three and six months ended June 30, 2025.
Participants can pre-register for the call through a provided link, or join by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A replay will be available until August 7, 2025, accessible via phone or webcast.
OPKO Health (NASDAQ: OPK) and Entera Bio announced their abstract on oral GLP-2 tablet for Short Bowel Syndrome (SBS) treatment has been selected for presentation at the 47th ESPEN Congress in Prague this September.
The research combines OPKO's proprietary long-acting GLP-2 agonist with Entera's N-Tab™ technology, aiming to provide an oral alternative to GATTEX® (teduglutide), which currently requires daily subcutaneous injections. The oral tablet format could potentially improve treatment compliance and enable more personalized care for SBS patients.
NextPlat (NASDAQ: NXPL) has issued an interim CEO update following the unexpected passing of former CEO Charles M. Fernandez. Interim CEO David Phipps outlined the company's strategic direction, focusing on two main divisions: Healthcare and E-Commerce.
In the Healthcare division, which represents the largest part of their business, NextPlat plans to expand contracted 340B and long-term care services, implement operational efficiencies, and pursue specialty medication accreditation. Key initiatives include exploring nationwide licensing for e-Commerce mail-order sales, adding compounding services, and targeting non-insured cash sales.
For the E-Commerce division, despite facing challenges from U.S.-China tariffs affecting product launches like their Florida Sunshine vitamin brand, the company aims to scale globally through strategic acquisitions, new marketplace launches, and partnerships. Notable developments include expanding their partnership with OPKO Health (NASDAQ: OPK) for health product sales in China and exploring UK/EU markets for their vitamin brand.
The company has also committed to implementing a previously announced stock buyback program and improving shareholder transparency while focusing on generating positive operating results.
OPKO Health (NASDAQ:OPK) announced its participation in the upcoming 3rd Annual Piper Sandler Virtual Obesity Symposium on June 26, 2025. The company's management will engage in a fireside discussion moderated by Edward Tentoff, Managing Director and Senior Biotechnology Analyst at Piper Sandler. Interested investors can register for the virtual event through their Piper Sandler representatives.
OPKO Health (NASDAQ: OPK) and Entera Bio announced their abstract for oral OPK-88006, a novel dual GLP-1/glucagon peptide treatment, has been selected for presentation at ENDO 2025 in San Francisco. The treatment is being developed as both a once-daily tablet and a weekly subcutaneous injection for patients with obesity and metabolic disorders.
The oral program combines OPKO's long-acting oxyntomodulin analog with Entera's N-Tab™ technology. The companies plan to file an IND application with the FDA later in 2025, followed by Phase 1 clinical studies. The presentation will showcase new pharmacologic and pharmacokinetic in vivo data at the conference on July 13, 2025.